In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|March 27, 2020
Asymmetrex’s New Algorithms Offer Low Cost Rapid Cell Counting
Author(s)BioPharm International Editors
The company has developed mathematical algorithms that generate simple cell-count data from a few days of culture.
Advertisement
Asymmetrex, a Boston, MA-based stem-cell biotechnology company, has discovered mathematical algorithms that allow simple cell count data from a few days of cell culture, which can be used to calculate the stem-cell-specific count of a sample. The new stem cell algorithms address the need for timely, inexpensive stem-cell-specific counting, the company reported in a March 5, 2020 press release.
The new stem cell algorithms are now a part of the company’s AlphaSTEM technology offering, launched in September 2016. The AlphaSTEM platform provides cell-specific count or dose of tissue stem cells. Adoption of the technology has been limited, however, despite the need for more accurate stem cell counting capabilities in academic stem cell research, stem cell biomanufacturing, and stem cell medicine.
“There’s a lot of misinformation in the stem cell industry about the nature of tissue stem cell preparations and how counting stem cells specifically would solve many of the current problems faced by the industry and patients,” said James Sherley, MD, PhD, founder and director of Asymmetrex, in a company press release.
With the discovery of the new algorithms, however, Asymmetrex is now accelerating efforts to identify investors and industry partners who market basic cell counter devices. The company plans to integrate the new algorithms with existing electronic cell counters to develop the first tissue stem cell counters for tissue stem cell research, tissue stem cell biomanufacturing, and stem cell therapies.
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5